Premium
Niprisan (Nix‐0699) improves the survival rates of transgenic sickle cell mice under acute severe hypoxic conditions
Author(s) -
Iyamu Efemwonkiekie W.,
Turner Ernest A.,
Asakura Toshio
Publication year - 2003
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1046/j.1365-2141.2003.04536.x
Subject(s) - valine , hypoxia (environmental) , acute chest syndrome , chemistry , hemoglobin , cell , medicine , sickle cell anemia , pharmacology , oxygen , amino acid , biochemistry , organic chemistry
Summary. The substitution of glutamic acid by valine at the sixth position of the beta‐globins of haemoglobin S (Hb S) causes a drastic reduction in the solubility of the deoxy form of Hb S. Under hypoxic conditions, deoxy‐Hb S molecules polymerize inside the cells, forming rigid, sickled cells. We studied the effect of Niprisan (Nix‐0699), a naturally occurring antisickling agent, on the survival of transgenic (Tg) sickle mice under severe acute hypoxic conditions (60 min). Before hypoxia exposure, the mice were treated by gavage once daily for 7 d with 0 mg/kg ( n = 10), 10 mg/kg ( n = 5), 50 mg/kg ( n = 5), 300 mg/kg ( n = 4) or 500 mg/kg ( n = 5) of Nix‐0699. The mean survival times of the untreated and treated mice were 10, 25, 39, 55 or 60 min respectively. The percentage of sickled cells in the venous blood of the treated mice was lower than that in control mice and was dose dependent. Histological examination of the lungs of the control mice showed entrapment of massive numbers of sickled cells in the alveolar capillaries, although the degree of such entrapment decreased with the increased dose of Nix‐0699. Nix‐0699 may be a promising option for the treatment and management of patients with sickle cell disease.